Adapted from literature. [1] 5-Iodouridine (15.3 g, 40.6 mmol) was charged in an oven-dried RBF and co-evaporated with pyridine (2 × 15 mL) and toluene (15 mL). DMF (324 mL) was added and the RM was cooled to 0 °C. tBu2Si(OTf)2 (13.9 mL, 41.4 mmol) was added to the RM with a syringe pump over 20 minutes. After a total of 1 hour, imidazole (13.8 g, 203 mmol) was added and the RM was left to stir at 0 °C for additional 30 minutes. TBDMS-Cl (15.3 g, 101 mmol) was added and the RM was stirred at RT for 12 hours. The reaction mixture was diluted with water (700 mL) and extracted with EtOAc (800 mL). The aqueous phase was extracted with EtOAc (500 mL), and the combined organic phases were concentrated to circa 200 mL. The organic phase was washed with water (2 × 200 mL) and brine (200 mL). The organic phase was dried over Na2SO4, filtered and concentrated. The residue was loaded to Celite and purified by flash column chromatography (330 g SNAP column, EtOAc in heptane, 0-30%) to afford 21.3 g (84%) of the title compound as a white solid.
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2-amino-5-nitrobenzene-1-thiol (2) [2]
Special safety measures for handling hydrazine: BARRIER © chemical resistant gloves were used in combination with nitrile gloves, enhanced ventilation in fume hood.
6-nitrobenzothiazole (25.0 g, 133 mmol) was dissolved in EtOH (99.5%, 250 mL). Hydrazine hydrate (64% hydrazine, 61 mL, 805 mmol) was added, and the RM was evacuated and refilled with nitrogen 3 times. The RM was stirred at RT for 18 hours, after which it was diluted with aqueous HCl (1 M, 1 L).
The mixture was extracted with CH₂Cl₂ (3 × 400 mL). The combined organic phases were washed with brine (2 × 300 mL), dried on a phase separator and concentrated, affording 18.5 g (84%) of the title compound as an orange solid. Used in the next step without further purification. 
5-[(2-amino-5-nitrophenyl)sulfanyl]-2'-O-[tert-butyl(dimethyl)silyl]-3',5'-O-(di-tertbutylsilylidene)uridine (3)
Compound 1 (12.5 g, 20.0 mmol) was charged into an oven-dried RBF, followed by the addition of CuI (1.43 g, 7.48 mmol), Cs2CO3 (7.24 g, 22.2 mmol), and 2 (5.7 g, 33.4 mmol). DMSO (100 mL) was added, and the RM was stirred at 60 °C for 24 hours. The RM was cooled to RT and diluted with water (400 mL) and EtOAc (400 mL) resulting in a black homogenous mixture. The mixture was vacuum filtered through a pad of Celite, whereupon a black wax was collected on top of the Celite pad. The filtrate, now partitioned into 2 phases, was collected. The wax was thoroughly washed with EtOAc (3 x 80 mL) and the combined washes were added to the filtrate. The combined fractions were partitioned. The aqueous phase was washed with EtOAc (2 × 150 mL). The combined organic fractions were washed with water (2 × 500 mL) and brine (2 × 200mL) . The organic phase was dried over MgSO4, filtered and concentrated. The residue was loaded onto Celite and purified by flash column chromatography (330 g SNAP column, EtOAc in heptane: 7-30%) to provide 10.86 g (81%) of the title compound as a yellow solid. 
3-{2-O-[tert-butyl(dimethyl)silyl]-β-D-ribofuranosyl}-7-nitro-3H-pyrimido[5,4-b][1,4]benzothiazin-2(10H)-one (4)
Compound 3 (9.24 g, 13.9 mmol) and PyBOP (14.9 g, 28.0 mmol) were charged in an oven-dried RBF. MeCN (267 mL) was added, and the RM was cooled to 0 °C. DBU (9.6 mL, 62.3 mmol) was added as a solution in MeCN (24 mL) with a syringe pump over 7 minutes. After a total of 1 hour the RM was allowed to return to RT. After a total of 4 hours, the reaction was quenched with aq. HCl (3.8 M, 100 mL) at 0 °C. The mixture was diluted with water (200 mL) and extracted with DCM (3 × 300 mL). The combined organic phases were dried on a phase separator, concentrated, loaded onto Celite and washed on a short silica plug (eluent: EtOAc in heptane 1:1). The collected solution was concentrated, and the resulting orange solid (20.6 g)
was used in the next step without further purification.
Special safety measures for handling HF: BARRIER © chemical resistant gloves were used in combination with nitrile gloves, enhanced ventilation in fume hood. An open bottle of sat. aq. Ca(OAc)2 was kept in the fume hood in case a spill/exposure of HF-pyridine would occur.
The deprotection protocol was adapted from literature. [1] Crude 3a (20.6 g) was charged in an ovendried RBF. CH2Cl2 (137 mL) was added and the RM was cooled to 0 °C. HF-pyridine (70% HF, 1.89 mL, 15.24 mmol) was added as a solution in pyridine (5 mL) over 1 minute. The reaction was quenched after a total of 6 hours with sat. aq. Ca(OAc)2 (50 mL) and stirred vigorously at RT for 20 minutes. The mixture was partitioned between CH2Cl2 (300 mL) and water (200 mL). The aqueous phase was extracted with CH2Cl2 (2 × 300 mL). The combined organic fractions were dried on a phase separator, concentrated and loaded onto Celite. The product was purified by flash column chromatography (330 g SNAP column, EtOAc in heptane: 20-80%) to afford 4.65 g (65% after two steps) of the title compound as a bright orange solid. 
3-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2-O-[tert-butyl(dimethyl)silyl]-β-D-ribofuranosyl}-7nitro-3H-pyrimido[5,4-b][1,4]benzothiazin-2(10H)-one (4a)
Compound 4 (1.48 g, 2.91 mmol) was charged in an oven-dried RBF. Pyridine (9.7 mL) was added, and the RM was cooled to 0 °C. DMTr-Cl (1.13 g, 3.33 mmol) was added in one portion. After 30 minutes the RM was allowed to return to RT. The reaction was quenched after a total of 4 hours by adding MeOH (0.75 mL), and was stirred for 10 more minutes. The mixture was partitioned between CH2Cl2 (50 mL) and aq. NaHCO3 (8%, 50 mL). The aqueous phase was extracted with CH2Cl2 (3 × 50 mL). The combined organic phases were dried on a phase separator, concentrated, and the residue loaded on Celite. The product was purified by flash column chromatography (50 g SNAP column; EtOAc in heptane: 10-60%) to provide 1.67 g (71%) of the title compound as a bright orange solid. 
3-(5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2-O-[tert-butyl(dimethyl)silyl]-3-O-{(2cyanoethoxy)[di(propan-2-yl)amino]phosphanyl}-β-D-ribofuranosyl)-7-nitro-3H-pyrimido[5,4b][1,4]benzothiazin-2(10H)-one (5)
Compound 4a (711 mg, 0.88 mmol) was charged in an oven-dried RBF. THF (10 mL) was added, followed by addition of DIPEA (0.61 mL, 3.51 mmol), and subsequent dropwise addition of CEP-Cl (0.39 mL, 1.75 mmol) over 1 minute. The RM was stirred at RT for 20 hours, upon which it was diluted with Et2O (25 mL). The mixture was washed with cold NaHCO3 (8%, 50 mL). The aqueous phase was extracted with cold Et2O (25 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated. The residue was re-dissolved in CH2Cl2 (3 mL) and applied on a samplet, which was beforehand treated with 2% TEA in heptane. The product was purified by flash column chromatography (50 g SNAP column, pre-treated with 2% TEA in heptane; EtOAc in heptane: 20-100%, both eluents contained 2% TEA) to provide 805 mg (91%) of the title compound as an orange solid. 
Oligonucleotide synthesis and purification
The oligoribonucleotides used for the A-RNA benchmark study (Figure 2a in main text) were synthesised using an ÄKTA oligopilot plus 10 synthesiser (GE Healthcare), using a standard 5 µmole phosphoramidite cycle of acid-catalyzed detritylation, coupling, capping and iodine oxidation. All β-cyanoethyl phosphoramidite monomers with 2′O-tert-butyldimethylsilyl (TBDMS) protection (Sigma-Aldrich; tC O was synthesised according to literature, [3] tCnitro was synthesised as shown in the synthesis section) were dissolved in anhydrous MeCN to a concentration of 0.1 M immediately prior to use. The coupling time for all phosphoramidite monomers was 20 minutes. Stepwise coupling efficiencies and overall yields were determined by automated trityl cation conductivity monitoring and in all cases were >96%. Oligoribonucleotides were cleaved from the support and base deprotected in a 1:3 EtOH/ammonia (aq. 26%) solution at 55 °C for 3 h and evaporated to dryness. Removal of TBDMS protecting groups was achieved by redissolving oligoribonucleotides in 625 µL dimethyl sulfoxide to which was added 625 µL 1 M triethylamine trihydrofluoride (Aldrich) and incubating at 65 °C for 2.5 hours prior to butanol precipitation. All oligoribonucleotides were purified by reverse-phase HPLC using a XBridge BEH column (C18, 19 × 150 mm, 5 µm, 130 Å pore), using an MeCN gradient with an aqueous phase of 100 mM triethylammonium acetate (pH 7.2). After HPLC purification, oligoribonucleotides were freeze-dried, then dissolved in phosphate buffer without the need for desalting. The oligoribonucleotides sequences used for investigating the transition from A-to Z-form RNA were purchased from ATDBio (Southampton, UK). Tables   Table S1. 5′-GtC O GCGCGCGCGC G C-3′ 3′-C G CGCGCGCGCGtCnG-5′ 0.49 0.08 0.53 0.10 a The DX and AY notation of the duplexes reflects the position of the donor, tC O (blue), and acceptor, tCnitro (tCn; orange) counting from the 5′-end of the GC-repeat of the donor-containing sequence. b Placement of the donor and acceptor in the GC-repeat of the sequences used for the A-to Z-RNA study. For the full structure, see main text Figure 2b . The duplexes were prepared as described in the "Materials and Methods" section and measured at RT. A-form duplexes were measured in phosphate buffer, pH 7.4, 123 mM Na + . Z-form duplexes were measured in phosphate buffer, pH 7.4, with 8 M NaClO4. c Z-form steady-state FRET efficiencies were corrected for variations in the concentration arising from the mixing with solid NaClO4. d The amount of dark species for separations seven and nine is estimated to be roughly 20% and 30% respectively, based on the difference in FRET efficiency from lifetime and steady-state measurements. a Duplexes were formed as described in the experimental section and measured at RT. b Placement of the donor in the GC-repeat of the sequences used for the A-to Z-RNA study. For the full structure, see main text Figure  2b . A-form duplexes were measured at RT in phosphate buffer, pH 7.4, 123 mM Na + . Z-form duplexes were measured at RT in phosphate buffer, pH 7.4, with 8 M NaClO4. c Quantum yields were determined with quinine sulfate as a reference (Φf = 54.6% in 0.5 M H2SO4) using an excitation wavelength of 356 nm.
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